Pretargeted radioimmunotherapy (PRIT) with TF2, an anti-CEA x anti-HSG bispecific antibody, and 177Lu-labeled di-HSG-DOTA peptide IMP288, can delay tumor growth of CEA-expressing colon cancer xenografts. The therapeutic efficacy of PRIT may be improved by using alpha-emitting radionuclides. The aim of this study was to assess the potential of 213Bi for PRIT.
HESKAMP Sandra;
HERNANDEZ Reinier;
ESSLER Markus;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
OYEN Wim;
SEIDL C.;
MCBRIDE William;
GOLDENBERG David;
BOERMAN Otto;
2015-07-14
SOC NUCLEAR MEDICINE INC
JRC94668
0161-5505,
http://jnm.snmjournals.org/content/56/supplement_3.toc,
https://publications.jrc.ec.europa.eu/repository/handle/JRC94668,
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|